Previous 10 | Next 10 |
JERSEY CITY, N.J. , March 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% conve...
JERSEY CITY, N.J. , Feb. 28, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present new in vivo data supporting the po...
Gainers: SPI Energy (NASDAQ: SPI ) +45% . SilverSun Technologies (NASDAQ: SSNT ) +30% . Proteostasis Therapeutics (NASDAQ: PTI ) +26% . Enochian Biosciences ( OTCQB:ENOB ) +20% . Nemaura Medical (NASDAQ: NMRD ) +19% . Select Interior Concepts (NASDAQ: SIC ) +18% . Replimune Gro...
This is not my first article on SCYNEXIS, Inc. (Scynexis) (SCYX), as readers who follow my ideas may know. I have been pounding the table on Scynexis for two years now. Unfortunately, the stock took a beating with the rest of the anti-infectives sector. The stock doubled last week after releas...
CORAL GABLES, FL / ACCESSWIRE / January 31, 2019 / The biotech stock market has evolved over the years in tandem with new technologies designed to tackle the world's most threatening diseases. Though the field of biotech is relatively new, companies in the industry have gone to g great len...
Nano cap SCYNEXIS (NASDAQ: SCYX ) is up 26% after hours in response to positive preliminary data from an open-label Phase 3 clinical trial, FURI , evaluating oral ibrexafungerp (formerly SCY-078) as a salvage treatment in patients with treatment-resistant mucocutaneous and inv...
JERSEY CITY, N.J. , Jan. 30, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first interim efficacy analysis of the ongoing F...
JERSEY CITY, N.J. , Nov. 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conf...
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
JERSEY CITY, N.J. , Oct. 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the successful completion of an End-of-Phase 2 Meeting with the U.S. Food a...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...